Why clinically differentiated assets miss market expectations in pharma launch strategy

With one-third of clinically differentiated drug launches failing to meet expectations within three years, the problem isn’t weak science or poor execution alone. It’s a structural misalignment between where launch teams invest and what actually drives adoption.

To understand why strong products underperform, ZS studied 340 drug launches and analyzed prescribing drivers among 690 U.S. board-certified specialists. The findings show what happens when organizations overinvest in clinical barriers and promotional intensity while underinvesting in the system around the therapy.

Key insights include:

• Why product attributes may explain far less about adoption behavior than physicians’ stated priorities suggest
• How people, support services and manufacturer reputation shape launch performance after a therapy clears the clinical threshold
• Why launch teams often focus on “why to prescribe” while underfunding what happens after the prescribing decision
• How high-performing organizations invest earlier in access infrastructure, barrier removal, support architecture and institutional follow-through
• What launch leaders can do to build commitment architecture that compounds across the portfolio

For pharma organizations, sustained launch performance through 2026-2030 and beyond will depend on building operating systems that help clinical innovation reach more patients and make launch investments more durable across therapeutic areas.